What is the appropriate diagnostic work‑up and treatment strategy for restless‑legs syndrome when dopamine agonists are avoided?

Treatment Strategy for Restless Legs Syndrome When Avoiding Dopamine Agonists

When dopamine agonists are discouraged, start with α2δ calcium channel ligands (gabapentin enacarbil, gabapentin, or pregabalin) as first-line pharmacotherapy, combined with iron repletion in patients with appropriate iron parameters. 1

Diagnostic Work-Up

Clinical Diagnosis

RLS diagnosis is purely clinical—no objective test exists. Confirm the four essential criteria:

• Urge to move legs (often with dysesthesias) when immobile
• Relief with movement
• Symptoms worse in evening/night
• Not better explained by mimics (neuropathy, akathisia, spasticity, positional discomfort, joint pain, nocturnal leg cramps, growing pains in children)

Iron Status Assessment

Check iron parameters in all RLS patients before initiating treatment:

• Serum ferritin
• Transferrin saturation

This is critical because iron deficiency is a core pathophysiological driver and a primary treatment target 1, 2.

Treatment Algorithm

First-Line Pharmacotherapy (Strong Recommendations)

1. α2δ Calcium Channel Ligands - Choose one:

• Gabapentin enacarbil (strong recommendation, moderate certainty) 1
• Gabapentin (strong recommendation, moderate certainty) 1
• Pregabalin (strong recommendation, moderate certainty) 1

These agents are now the mainstay of RLS treatment, having replaced dopamine agonists due to their efficacy without augmentation risk 3, 4.

2. Intravenous Iron Therapy (when iron parameters are appropriate):

• IV ferric carboxymaltose (strong recommendation, moderate certainty) 1
  • Caution: More likely to cause hypophosphatemia than other IV iron formulations 3
• IV low molecular weight iron dextran (conditional recommendation) 1
• IV ferumoxytol (conditional recommendation) 1

Second-Line Options (Conditional Recommendations)

Oral Iron:

• Ferrous sulfate in patients with appropriate iron status 1

Other Pharmacological Options:

• Dipyridamole (conditional recommendation, low certainty) 1
• Extended-release oxycodone and other opioids (conditional recommendation, moderate certainty) 1
  • Data from the National RLS Opioid Registry show reassuring safety findings 3
  • Consider for refractory cases or severe augmentation from prior dopaminergic therapy 5

Non-Pharmacological:

• Bilateral high-frequency peroneal nerve stimulation (conditional recommendation, moderate certainty) 1
  • Demonstrated efficacy and safety as adjunct therapy in refractory RLS 3

Why Dopamine Agonists Are Discouraged

The 2025 AASM guidelines represent a paradigm shift, suggesting against standard use of all dopamine agonists due to long-term complications 1:

• Pramipexole (conditional recommendation against) 1
• Ropinirole (conditional recommendation against) 1
• Transdermal rotigotine (conditional recommendation against) 1
• Cabergoline (strong recommendation against) 1

Primary concern: Augmentation - the worsening of RLS symptoms with chronic dopaminergic use, characterized by:

• Earlier onset of symptoms during the day
• Shorter latency to symptoms when at rest
• Spread to other body parts
• Shorter duration of treatment effect 5, 2

While dopamine agonists provide robust short-term efficacy, their long-term risk-benefit profile has been fundamentally reconsidered 2. The guidelines note they may still be used in patients who "place a higher value on short-term symptom reduction and a lower value on long-term adverse effects," but this is explicitly not the standard approach 1.

Special Populations

End-Stage Renal Disease (ESRD):

• Gabapentin (conditional recommendation) 1
• IV iron sucrose if ferritin <200 ng/mL and transferrin saturation <20% (conditional recommendation) 1
• Vitamin C (conditional recommendation) 1

Children:

• Ferrous sulfate with appropriate iron status (conditional recommendation) 1

Pregnancy:

• Consider pregnancy-specific safety profile of each treatment 1
• Iron supplementation is particularly important

Critical Pitfalls to Avoid

1. Do not start daily pharmacotherapy for intermittent RLS - use behavioral measures and on-demand therapy instead 4

2. Address exacerbating factors first:

   • Discontinue or substitute medications: antihistamines, serotonergic agents, antidopaminergic drugs 1
   • Reduce alcohol and caffeine 1
   • Treat untreated obstructive sleep apnea 1

3. Do not ignore iron status - even without overt anemia, iron deficiency is a core therapeutic target 2

4. Avoid medications with no evidence or negative recommendations:

   • Bupropion (suggest against) 1
   • Carbamazepine (suggest against) 1
   • Clonazepam (suggest against) 1
   • Valproic acid (suggest against) 1
   • Valerian (suggest against) 1

Treatment Sequencing for Refractory Cases

If first-line α2δ ligands fail or are not tolerated:

1. Optimize iron status if not already done
2. Consider opioid monotherapy (bypassing dopamine agonists entirely) 5
3. Consider polytherapy combining α2δ ligands with other non-dopaminergic agents
4. Trial bilateral peroneal nerve stimulation as adjunct 3

This modern approach is augmentation-aware, iron-conscious, and phenotype-oriented, representing a fundamental shift toward sustainable long-term management rather than short-term symptom suppression 2.